Abstract
We report a patient with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who showed high titers of anti-sulfated glucuronyl paragloboside (SGPG) IgM antibody without M-protein in serum. The patient was resistant to corticosteroids and immunosuppressants, but after administration of rituximab, clinical symptoms improved and the patient remained in a stable state for approximately 10 months. Rituximab may be a potent therapeutic option for refractory cases of CIDP irrespective of detectable M-protein in either serum or urine.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents / therapeutic use*
-
Drug Therapy, Combination
-
Follow-Up Studies
-
Globosides / immunology*
-
Humans
-
Immunoglobulin M / therapeutic use*
-
Male
-
Neural Conduction / drug effects
-
Neural Conduction / physiology
-
Neural Conduction / radiation effects
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / drug therapy*
-
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / physiopathology
-
Reaction Time / drug effects
-
Reaction Time / radiation effects
-
Rituximab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents
-
Globosides
-
Immunoglobulin M
-
sulfate-3-glucuronyl paragloboside
-
Rituximab